Core Viewpoint - The company reported a revenue of 793 million yuan for the year 2025, representing a year-on-year growth of 15.49%, and a net profit attributable to the parent company of 144 million yuan, with a year-on-year increase of 31.49% [1] Group 1: Financial Performance - The company's revenue increased by 15.49% year-on-year, primarily due to the expansion of its overseas sales network covering North America, Europe, and the Asia-Pacific regions, leading to a growing customer base and enhanced brand recognition [1] - The net profit attributable to the parent company reached 144 million yuan, reflecting a significant year-on-year growth of 31.49% [1] Group 2: Strategic Focus - The company is focusing on two core strategies: internationalization and innovation, which include continuous efforts to expand overseas markets and maintain high levels of R&D investment [1] - The company is developing new platforms based on universal underlying technologies, such as a fully human antibody platform and a microbiome research platform, to accelerate the transformation of R&D results and provide new growth points for development [1] Group 3: Market Dynamics - The domestic market has benefited from an increase in industry prosperity and a resurgence in R&D investments from downstream industrial clients, leading to a notable recovery in demand from industrial customers [1] - The functional efficacy business of the company has shown rapid revenue growth due to the recovery in demand from industrial clients [1]